Plain-English translation of NCT06376916 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing magnesium sulfate — a mineral given through an IV — to help slow down a very fast heartbeat caused by atrial fibrillation or atrial flutter. Researchers want to find out whether a 2-gram dose, a 4-gram dose, or a placebo (inactive saline) works best at bringing your heart rate back to a safer level. This medication is already used in hospitals for this purpose, but doctors aren't sure what the ideal dose should be.
While this medication has helped many patients with racing heartbeats, there's no clear agreement among doctors about which dose works best. This study aims to answer that question so that treatment can be more effective and standardized.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a single intravenous infusion of either the 2-gram dose of magnesium sulfate, the 4-gram dose, or a placebo saline solution. You'll be randomly assigned to one of these three groups, and neither you nor the medical team will know which one you're receiving. The study will then monitor how well the treatment works at slowing your heart rate and controlling your symptoms.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Wake Forest University Health Sciences
Enrollment target
~153 participants
Started
October 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marc McDowell, PharmD
Wake Forest University Health Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.